ReviewFrontiers in oncology2024
Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma.
Review in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Conversion Surgery Versus Non-Surgical Treatment for Initially Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Impact of Collaborative Empowerment Education on Psychological Distress, Quality of Life, and Nutritional Status in Esophageal Cancer Patients Undergoing Concurrent Chemoradiotherapy.Journal of cancer education : the official journal of the American Association for Cancer Education · 2026Trial
- SNORA23-KDM5C epigenetic axis mediates dual DNA repair pathways to drive radioresistance in esophageal squamous cell carcinoma.Cell death and differentiation · 2026Article
- Phase II randomized trial of 41.4 Gy vs. 50.4 Gy in neoadjuvant chemoradiotherapy for resectable esophageal cancer.Clinical and translational radiation oncology · 2026Article
- Autophagy-centered gene networks reveal prognostic biomarkers and therapeutic targets in esophageal cancer.Discover oncology · 2026Article
- Development and validation of an m6A and autophagy related lncRNAs signature for predicting survival and modulating the immune microenvironment in esophageal squamous cell carcinoma.Frontiers in immunology · 2026Article
- Heart failure induced by cancer therapies: focus on targeted agents, mechanisms, risk prediction, and clinical management.Frontiers in pharmacology · 2026Review
- The survival impact of upfront or sequential chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.Frontiers in oncology · 2026Article
- Radiomics meets sarcopenia: Machine learning-based multimodal modeling for esophageal cancer outcomes.World journal of gastrointestinal oncology · 2025Review
- Expanding horizons in esophageal squamous cell carcinoma: The promise of induction chemoimmunotherapy with radiotherapy.World journal of clinical oncology · 2025Article
- CircSLC22A3 inhibits the invasion and metastasis of ESCC via the miR-19b-3p/TRAK2 axis and by reducing the stability of mBMC cancer · 2025Article
- Development and validation of a novel signature to predict the survival and affect the immune microenvironment of esophageal squamous cell carcinoma: epigenetic-related genes.Frontiers in immunology · 2025Article
- Prognostic value of the log odds of negative lymph nodes/T stage ratio (LONT) in postoperative esophageal cancer: a SEER-based study.Frontiers in oncology · 2025Article
- A nomogram for predicting cancer-specific survival in patients with locally advanced unresectable esophageal cancer: development and validation study.Frontiers in immunology · 2025Article
- Evolving Therapeutic Strategies in Esophageal Squamous Cell Carcinoma: Advances and Perspectives.Journal of cancer prevention · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal squamous cell carcinoma (ESCC) is an aggressive and fatal disease that is usually diagnosed when the chances for surgical intervention has been missed. Definitive concurrent chemoradiotherapy (dCRT) is the first choice of treatment for inoperable locally advanced esophageal squamous cell carcinoma (LA-ESCC). Nevertheless, the local recurrence rate for esophageal cancer patients undergoing dCRT remains high at 40-60%, with a 5-year overall survival rate of solely 10-30%. Immunotherapy in combination with dCRT is a promising treatment for inoperable LA-ESCC, for that improved long-term survival is expected. The present review provides a comprehensive overview of the evolutionary trajectory of dCRT for LA-ESCC, delineates notable relevant clinical studies, addresses unresolved concerns regarding the combination of dCRT with immunotherapy, and highlights promising directions for future research. When dCRT is combined with immunotherapy, the following aspects should be carefully explored in the future studies, including the optimal irradiation dose, segmentation scheme, radiotherapy technique, timing, sequence and duration of radiotherapy, and the selection of chemotherapeutic and immunologic drugs. In addition, further investigations on the mechanisms of how dCRT combined with immunotherapy exerts synergistic anti-tumor effects and molecular biomarkers ensuring precise screening of ESCC patients are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.